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Abstract
It is unknown if the cardioprotective and renal effects of glucagon-like peptide-1
receptor agonists are consistent across blood pressure (BP) categories in patients
with type 2 diabetes and at high risk of cardiovascular events. Using data from the
LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post
hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovas-
cular events (MACE) and nephropathy by baseline BP categories using a Cox propor-
tional hazards model (treatment and subgroup as factors; adjusted for cardiorenal risk
factors). Data from the two trials were analysed separately. In the LEADER and SUS-
TAIN 6 trials, the prevalence of stage 1 hypertension was 30% and 31%, respectively,
and of stage 2 hypertension 41% and 43%, respectively. There was no statistical het-
erogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE;
P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy)
versus placebo. This implies that liraglutide and semaglutide may be beneficial for
patients with type 2 diabetes, irrespective of their baseline BP.
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1 | INTRODUCTION
Elevated blood pressure (BP) is very common in people with type
2 diabetes (T2D), and increases the risk of cardiovascular (CV) and
renal events in this population.1,2 Glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) have been shown to reduce the incidence of CV
and renal events in people with T2D or at risk of CV disease.3,4 These
agents have also been shown to reduce BP versus placebo, insulin and
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sulphonylureas,5 with greater reductions observed in those with
higher baseline BP (liraglutide vs. placebo).6 Whether GLP-1 RAs exert
CV and renal event reduction in a consistent fashion across the spec-
trum of baseline BP remains unknown. Therefore, we studied this
question in the LEADER7 and SUSTAIN 68 trials, through separate
post hoc analyses.
2 | METHODS
The design, baseline patient characteristics and primary results of the
LEADER7 and SUSTAIN 68 trials have been reported previously.
Briefly, they were global, double-blind, placebo-controlled, random-
ized CV outcomes trials of subcutaneously injected liraglutide
(LEADER) and semaglutide (SUSTAIN 6), in patients with T2D (HbA1c
≥ 7.0%) and high CV risk. Institutional review boards or ethics com-
mittees for each centre approved the trial protocols and all patients
provided informed consent.7,8 The key inclusion criteria were
age ≥ 50 years with ≥1 co-existing CV condition (coronary heart dis-
ease, cerebrovascular disease, chronic kidney disease stage ≥3, or
chronic New York Heart Association class II or III heart failure) or
age ≥ 60 years with ≥1 CV risk factor. In both trials, CV risk factors
included microalbuminuria or proteinuria, hypertension and left ven-
tricular hypertrophy, left ventricular systolic or diastolic dysfunction,
or an ankle-brachial index of <0.9.7,8
Patients were followed for up to 5 years in the LEADER trial
(N = 9340; median time 3.8 years), and in the SUSTAIN 6 trial all
patients were followed for 2 years (N = 3297; median time
2.1 years).7,8 The primary composite outcome in both trials was the
first occurrence of major adverse cardiovascular events (MACE: CV
death, non-fatal myocardial infarction [MI] or non-fatal stroke).7,8 Sec-
ondary outcomes included a composite renal outcome of new-onset
persistent macroalbuminuria, persistent doubling of serum creatinine
level, the need for continuous renal replacement therapy or death
from renal disease. Expanded MACE included the events within pri-
mary MACE in addition to revascularization and hospitalization for
heart failure or unstable angina. CV and renal events were adjudicated
by an external, blinded, independent, expert committee. BP was mea-
sured at baseline and designated clinic visits (at least annually)
according to the usual practice at the investigator's site7,8 (further
details are available in the Supplementary Appendix, see the
supporting information).
2.1 | Statistics
In this post hoc analysis, the effects of liraglutide and semaglutide on
the primary CV and secondary new or worsening nephropathy out-
comes were evaluated by baseline American College of Cardiology/
American Heart Association-defined BP categories9: normal
(<120/80 mmHg), elevated (systolic 120-129 mmHg and diastolic
<80 mmHg), stage 1 hypertension (systolic 130-139 mmHg or dia-
stolic 80-89 mmHg) and stage 2 hypertension (systolic ≥140 mmHg
or diastolic ≥90 mmHg). The mean of two BP measurements taken at
the randomization visit (baseline) was used to assign the BP category.
A Cox proportional hazards model, with treatment and BP category as
factors and the interaction between both, was used to calculate the
hazard ratio (HR) and 95% confidence interval (CI). The model was
adjusted for baseline characteristics related to cardiorenal risk (age,
antihyperglycaemic medications, diabetes duration, geographic region,
history of MI or stroke, renal function as measured by estimated
glomerular filtration rate, sex, and smoking status [smoking status
was omitted for endpoints with low frequency in SUSTAIN 6]). An
interaction P-value of <.05 was considered significant. Analysis of
expanded MACE, hospitalization for heart failure, CV death and
all-cause mortality was also performed using the Cox proportional
hazards model as described. The analysis of MACE and nephropa-
thy was repeated with patients further categorized by angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker (ACEi/
ARB) use at baseline. For all tests, P-values were not adjusted for
multiple comparisons. Quadratic spline regression applied using a
Cox proportional hazard model was used to analyse the treatment
differences in time to first MACE by systolic and diastolic BP on a
continuous scale.
To further test potential interactions between BP categories and
treatment, the Gail-Simon test (for qualitative interactions) was
applied in the Cox proportional hazard model, where a P-value of <.05
would indicate that the direction of treatment effect differed in one
or more subgroups versus the remaining subgroups, e.g. that a treat-
ment increased the risk in one subgroup, while simultaneously
decreasing risk in another subgroup for an endpoint. The Gail-Simon
test differed from the interaction test (which measured quantitative
interactions), wherein small P-values would indicate that the magni-
tude of the treatment effects differed between subgroups. All ana-
lyses were performed using the statistical software package SAS
version 9.4.
3 | RESULTS
All patients randomized in the LEADER (n = 9340) and SUSTAIN
6 (n = 3297) trials were included in these analyses. The baseline char-
acteristics of patients in each BP category in LEADER and SUSTAIN
6 are shown in Tables S1 and S2, respectively. In the LEADER and
SUSTAIN 6 trials, the prevalence of stage 1 hypertension was 30%
and 31%, respectively, and the prevalence of stage 2 hypertension
was 41% and 43%, respectively.
3.1 | Cardiorenal efficacy across BP categories in
LEADER and SUSTAIN 6
Figure 1 depicts the HRs for the primary MACE and renal outcomes in
LEADER (Figure 1A) and SUSTAIN 6 (Figure 1B) trials across the BP
categories studied. In both instances, treatment with liraglutide or
semaglutide versus placebo was associated with a consistent
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reduction in cardiorenal outcomes with no evidence of statistical het-
erogeneity. Although there appeared to be a trend with liraglutide
versus placebo towards a lower relative risk reduction in those with
normal BP (compared with those with stage 1 or 2 hypertension), this
was not statistically significant (P-interaction = .06). The Gail-Simon
test for qualitative interaction revealed no significant interaction for
the primary MACE or nephropathy outcomes in LEADER or SUSTAIN
6, respectively (Figure 1A,B).
Additional outcomes, including expanded MACE, hospitalization
for heart failure and all-cause mortality, are depicted in Tables S3 and
S4, and generally supported a conclusion of consistent benefit for
liraglutide and semaglutide across the BP categories. For the
expanded MACE outcome (which included CV death, non-fatal MI,
non-fatal stroke, coronary revascularization, hospitalization for unsta-
ble angina or heart failure), the P-value for interaction was .048 in
LEADER, and was non-significant in SUSTAIN 6. Analysis by ACEi/
Favours liraglutide Favours placebo 
1 100.1
N with event (%)






LEADER overall7 )79.0–87.0( 78.0)9.41( 496)0.31( 806
)23.1–57.0( 00.1)2.41( 001)2.41( 89lamron PB
)86.1–78.0( 12.1)9.9( 46 )1.21( 08detavele PB
)09.0–06.0( 37.0)8.41( 802 )2.11( 651noisnetrepyh1egats PB
99.0–27.0( 48.0)9.61( 223)3.41( 472noisnetrepyh2egats PB
Nephropathy‡
LEADER overall7 )29.0–76.0( 87.0)2.7( 733)7.5( 862
)63.1–84.0( 18.0)4.4( 13)8.3( 62lamron PB
)68.1–86.0( 21.1)3.4( 82 )0.5( 33detavele PB
)97.0–24.0( 85.0)2.7( 201 )4.4( 16noisnetrepyh1egats PB
)00.1–56.0( 08.0)2.9( 671 )7.7( 841noisnetrepyh2egats PB
0.06 0.39
0.14 0.70
Favours semaglutide Favours placebo 
1 100.10.01
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BP stage 1 hypertension





BP stage 1 hypertension
BP stage 2 hypertension
0.40 0.88
0.27 0.88
108 (6.6) 146 (8.9) 0.74 (0.58–0.95)
15 (6.9) 19 (8.7) 0.79 (0.40–1.56)
9 (4.1) 22 (10.0) 0.43 (0.20–0.95)
24 (4.8) 37 (7.2) 0.62 (0.37–1.03)
60 (8.4) 68 (9.8) 0.85 (0.60–1.21)
62 (3.8) 100 (6.1) 0.64 (0.46–0.88)
)50.1–11.0( 43.0)5.5( 21)8.1( 4
)48.0–70.0( 42.0)3.6( 41 )4.1( 3
19 (3.8) 25 (4.8) 0.69 (0.38–1.26)
)11.1–74.0( 27.0)1.7( 94 )1.5( 63
F IGURE 1 Cardiorenal outcomes by baseline blood pressure (BP) category, adjusted for baseline variables related to cardiorenal risk, in the
LEADER (A) and SUSTAIN 6 trials (B). †Primary major adverse cardiovascular events (MACE): composite of cardiovascular death, non-fatal
myocardial infarction (MI) and non-fatal stroke. Analysis adjusted for baseline characteristics related to cardiorenal risk (age, antihyperglycaemic
medications, diabetes duration, geographic region, history of MI or stroke, renal function as measured by estimated glomerular filtration rate, sex,
and smoking status). ‡Nephropathy (new or worsening): new or persistent macroalbuminuria, doubling of serum creatinine, end-stage kidney
disease or death from kidney disease. §Analysis adjusted as for MACE, with the omission of smoking status because of a low number of events.
BP categories were defined as follows: normal = systolic blood pressure (SBP) < 120 mmHg, diastolic blood pressure (DBP) 80 mmHg;
elevated = SBP 120-129 mmHg and DBP < 80 mmHg; stage 1 hypertension = SBP 130-139 mmHg or DBP 80-89 mmHg; stage 2
hypertension = SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. CI, confidence interval; HR, hazard ratio
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ARB use at baseline in both trials also revealed a consistent benefit
across all categories (Figures S1 and S2).
Analysis of systolic and diastolic BP at baseline as continuous var-
iables confirmed a consistent benefit of liraglutide or semaglutide
within the quartile boundaries (i.e. end of Q1 to beginning of Q3), in
which 50% of the events occurred (Figure 2).
4 | DISCUSSION
GLP-1 RAs are known to have multiple favourable cardiometabolic
effects on glycaemia, weight and blood pressure.3,7,8 While the CV
benefits of these therapies are unlikely to be solely dependent on
these effects10,11 and are also suggested to be modulated by direct
vasculoprotective/antiatherosclerotic pathways,12,13 questions have
been raised about whether these therapies exert cardiorenal benefits
in the setting of adequate risk factor control. The present analyses,
from two large and contemporary randomized controlled trials, sug-
gest that liraglutide and semaglutide provide similar benefits, both
quantitatively and qualitatively, on major cardiorenal outcomes in
people with T2D across the spectrum of baseline BP values. Even in
patients with normal BP on entering both of these trials, these bene-
fits were seen for both GLP-1 RAs. These data, taken together with
prior analyses from LEADER and SUSTAIN 6 showing efficacy across
the spectrum of lipid levels11,13 and body mass index,14 suggest that
these therapies should be considered as complementary to traditional
risk factor modification for risk reduction in people with T2D.
Indeed, when examining data related to BP, it can be important to
consider traditional risk factor modifications in terms of medications
frequently prescribed for this purpose, such as ACEis and ARBs. We
noted that the benefits with GLP-1 RAs were consistently observed in
users and non-users of ACEis/ARBs, suggesting that the cardiorenal
benefits of liraglutide and semaglutide are probably additive to that of
renin-angiotensin system blockade. Future studies could further
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F IGURE 2 Quadratic spline regression treatment differences in time to first major adverse cardiovascular events (MACE), according to
baseline systolic blood pressure (SBP) (A and B) and diastolic blood pressure (DBP) (C and D), in the LEADER (A and C) and SUSTAIN 6 (B and D)
trials. Primary MACE: composite of cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke. Q1, one quarter of patients
had a lower blood pressure (BP) value than this. Median, half of patients had a lower BP value than this. Q3, three-quarters of patients had a
lower BP value than this. BP categories were defined as follows: normal = SBP < 120 mmHg, DBP 80 mmHg; elevated = SBP 120-129 mmHg and
DBP < 80 mmHg; stage 1 hypertension = SBP 130-139 mmHg or DBP 80-89 mmHg; stage 2 hypertension = SBP ≥ 140 mmHg or DBP
≥ 90 mmHg. LCL, lower confidence limit; Q, quartile; St., stage; UCL, upper confidence limit
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explore this to determine exactly how GLP-1 RAs confer such cardio-
renal benefits, independently of the renin-angiotensin system.
Limitations of this post hoc analysis include that it was a retro-
spective analysis of data from two different trials, not powered to
look at endpoints in these subgroups, and only baseline and not in-
trial BP categories were considered. Furthermore, BP was recorded
using different techniques, as per the usual practice at each site,
which may have had an impact on the measurements. In addition, the
use of antihypertensive medication during the trial was at the discre-
tion of the investigator and was not examined as a time-varying
covariate. Competing risk factors (e.g. non-CV death) may have also
impacted the results, and there was no adjustment for biomarkers in
this analysis, as has been performed in other similar analyses.15
In conclusion, in both LEADER and SUSTAIN 6, liraglutide and
semaglutide showed no heterogeneity of efficacy in CV and renal out-
comes, irrespective of baseline BP categories and of ACEi/ARB use.
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